Paving the path to HIV neurotherapy: Predicting SIV CNS disease

Eur J Pharmacol. 2015 Jul 15:759:303-12. doi: 10.1016/j.ejphar.2015.03.018. Epub 2015 Mar 24.

Abstract

HIV-induced damage to the CNS remains a major challenge for over 30 million people in the world despite the successes of combined antiretroviral therapy in limiting viral replication. Predicting development and progression of HIV-associated CNS disease is crucial because prevention and early intervention could be more effective than attempts to promote repair. The SIV/macaque model is the premier platform to study HIV neuropathogenesis, including discovery of predictive factors such as neuroprotective host genes and both blood and CSF biomarkers that precede and predict development of SIV CNS disease. This report details the role of macaque MHC class I genes, longitudinal alterations in biomarkers in the circulation, and expression of inflammatory and neuronal damage markers in CSF using samples from SIV-inoculated pigtailed macaques collected during acute, asymptomatic, and terminal stages of infection.

Keywords: CCL2; CSF; HIV; IL-6; MHC class I; Pigtailed macaque; Platelets; SIV.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • AIDS Dementia Complex / blood
  • AIDS Dementia Complex / cerebrospinal fluid
  • AIDS Dementia Complex / drug therapy*
  • AIDS Dementia Complex / virology
  • Animals
  • Biomarkers / blood
  • Biomarkers / cerebrospinal fluid
  • Disease Models, Animal*
  • Humans
  • Macaca nemestrina
  • Neuroprotective Agents / therapeutic use
  • Predictive Value of Tests
  • Simian Acquired Immunodeficiency Syndrome / blood
  • Simian Acquired Immunodeficiency Syndrome / cerebrospinal fluid
  • Simian Acquired Immunodeficiency Syndrome / drug therapy*
  • Simian Acquired Immunodeficiency Syndrome / virology
  • Simian Immunodeficiency Virus

Substances

  • Biomarkers
  • Neuroprotective Agents